國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁 到查詢結果 [ subject:"Cystic fibrosis" ]

切換: 標籤 | MARC模式 | ISBD

Treatment of cystic fibrosis and oth...

Azuma, Arata.

Treatment of cystic fibrosis and other rare lung diseases

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Treatment of cystic fibrosis and other rare lung diseasesedited by Arata Azuma, Michael S. Schechter.
其他作者:	Azuma, Arata.
出版者:	Basel :Springer Basel :2017.
面頁冊數:	viii, 263 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Cystic fibrosisTreatment.
電子資源:	http://dx.doi.org/10.1007/978-3-0348-0977-1
ISBN:	9783034809771$q(electronic bk.)

Treatment of cystic fibrosis and other rare lung diseases
Treatment of cystic fibrosis and other rare lung diseases[electronic resource] /edited by Arata Azuma, Michael S. Schechter. - Basel :Springer Basel :2017. - viii, 263 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

ISBN: 9783034809771$q(electronic bk.)

Standard No.: 10.1007/978-3-0348-0977-1doiSubjects--Topical Terms:

731857
Cystic fibrosis
--Treatment.

LC Class. No.: RC858.C95

Dewey Class. No.: 616.372

Treatment of cystic fibrosis and other rare lung diseases
LDR:02199nmm a2200325 a 4500 001 507088
003 DE-He213
005 20170201181627.0
006 m d
007 cr nn 008maaau
008 171030s2017 sz s 0 eng d
020 $a 9783034809771$q(electronic bk.)
020 $a 9783034809757$q(paper)
024 7 $a 10.1007/978-3-0348-0977-1 $2 doi
035 $a 978-3-0348-0977-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC858.C95
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.372 $2 23
090 $a RC858.C95 $b T784 2017
245 0 0 $a Treatment of cystic fibrosis and other rare lung diseases $h [electronic resource] / $c edited by Arata Azuma, Michael S. Schechter.
260 $a Basel : $b Springer Basel : $b Imprint: Springer, $c 2017.
300 $a viii, 263 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
520 $a This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
650 0 $a Cystic fibrosis $x Treatment. $3 731857
650 0 $a Lungs $x Diseases $x Treatment. $3 489272
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Pharmacology/Toxicology. $3 273652
650 2 4 $a Pneumology/Respiratory System. $3 274253
650 2 4 $a Internal Medicine. $3 273839
650 2 4 $a Immunology. $3 189152
700 1 $a Azuma, Arata. $3 773549
700 1 $a Schechter, Michael S. $3 773550
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 557479
856 4 0 $u http://dx.doi.org/10.1007/978-3-0348-0977-1
950 $a Biomedical and Life Sciences (Springer-11642)